ONCOGENE PHARMACEUTICALS
Name
Oncotype DX
Description
BGI’s Cancer+ Discovery Panel is designed to identify all classes of actionable genomic alterations, including SNP, CNV, InDels and Fusions, across a total of 508 cancer-related genes. Results are supported by in depth mutation analysis and pharmacogenomics information relating to 102 cancer therapeutics approved by the FDA or currently undergoing clinical trials.
Comprehensive
Whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
Recommended for
| Individuals having family history of cancer. |
Gene Panel
| 74 genes in female test package 79 genes in male test package. |
Comprehensive
| Whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements. |
Recommended for
| Patients suspected of being at increased risk of HBOC. |
Specimen
| Peripheral blood, DNA, Saliva. |
TAT
20 Calendar Days.
Regulatory Status
CLIA- Certified (Clinical Laboratory Improvement Amendments of 1988) CAP-accredited reference laboratory.
TEST LIST
GENE LIST
Sentis BRCA (2 genes) pane
| BRCA1, BRCA2 |
Sentis Hereditary Breast and Ovarian (26 genes) panel
BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1,NBN, MRE11A,MSH2, MSH6, MUTYH, PMS1,PMS2, RAD50, RAD51C, NF1, EPCAM, SMARCA4, HOXB13.
Name
BGI Sentis Hereditary cancer screening
Description
BGI’s Comprehensive Hereditary Cancer Panel provides information on 74-79 genes associated with 24 different types of hereditary cancer including some of the most commonly occurring cancers such as hereditary breast, ovarian, colorectal, prostate and stomach cancer. BGI detects different alterations including germline SNV, Indels and CNV.
Comprehensive
Whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
Recommended for
Individuals having family history of cancer.
Gene Panel
74 genes in female test package 79 genes in male test package.
Specimen
Specimen
TAT
20 Calendar Days.
TEST LIST
NIFTY-Non Invasive Fetal trisomy Test
PURPOSE
Screening of fetus for genetic disorders
NIFTY test is suitable for, but not limited to, patients which exhibit any of these indications
Maternal age 35 or older at delivery • Contradictions of invasive testing, and risk of miscarriage • History with prior pregnancy with chromosomal abnormality • Received IVF treatment • Previously suffered from Habitual abortion.
NIFTY test not suitable for patients with these indications:
Maternal/Fetal/Placental Mosaicism • Mother/ father have chromosomal abnormality • Patient who have received blood transfusion within one year prior to testing • Patients who had transplant surgery • Patients who have stem cell therapy • Vanishing twin syndrome.
Specimen
5ml Maternal Blood.
Validation
Clinically validated with proven >99% sensitivity based on a study of nearly 147,000 pregnancies.
Insurance Coverage
Different insurance policies are available in case of confirmatory invasive testings.
TAT
7 days.